Table 2.
The association between POLE mutated EC and clinicopathology characteristics
| Clinicopathological characteristics in EC | Pooled % portion (95% CI, %) | No. of studies | I2 (95% CI) | p-value | Model |
|---|---|---|---|---|---|
| Overall POLE mutation | 8.59 (7.01–10.32) | 25 | 78.10 (68.15–84.94) | < .001 | Random effect |
| POLE mutation in type I | 8.22 (6.27–10.42) | 9 | 74.88 (51.43–87.00) | < .001 | Random effect |
| POLE mutation in type II | 0.93 (0.34–1.81) | 10 | 75.32 (54.08–86.74) | < .001 | Random effect |
| Stage I–II | 89.51 (81.11–95.66) | 10 | 69.09 (40.43–83.96) | < .001 | Random effect |
| Stage III–IV | 14.77 (5.99–26.59) | 7 | 65.96 (23.79–84.79) | < .001 | Random effect |
| Grade I–II | 46.36 (30.66–62.43) | 7 | 82.15 (64.34–91.06) | < .001 | Random effect |
| Grade III | 51.53 (36.08–66.84) | 8 | 81.79 (65.23–90.46) | < .001 | Random effect |
| Lymphovascular invasion | 31.11 (10.44–56.86) | 8 | 93.34 (89.15–95.91) | < .001 | Random effect |
| Myometrial invasion less than 50% | 49.90 (43.71–56.21) | 7 | 22.10 (0.00–65.16) | 0.260 | Fixed effect |
POLE, DNA polymerase epsilon; EC, endometrial carcinoma; CI, confidence interval.